Results 51 to 60 of about 33,145 (233)

Myxoma virus protein M029 is a dual function immunomodulator that inhibits PKR and also conscripts RHA/DHX9 to promote expanded host tropism and viral replication. [PDF]

, 2013
Myxoma virus (MYXV)-encoded protein M029 is a member of the poxvirus E3 family of dsRNA-binding proteins that antagonize the cellular interferon signaling pathways.
Chan, Winnie M, Liu, Jia, McFadden, Grant, Rahman, Masmudur M, Rothenburg, Stefan   +4 more
core   +1 more source

Pre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors

Advanced Science, EarlyView.
Type I interferon (IFN‐I) signaling promotes p21‐dependent cell cycle arrest in senescent tumor‐specific memory T cells, resulting in poor proliferative responses and solid tumor regression during cancer vaccination. Conversely, IFNα/β receptor blockade reinvigorates T cell proliferation to regress solid tumors and is more effective with increasing ...
Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan   +4 more
wiley   +1 more source

Retargeted adenoviruses for radiation-guided gene delivery [PDF]

, 2016
The combination of radiation with radiosensitizing gene delivery or oncolytic viruses promises to provide an advantage that could improve the therapeutic results for glioblastoma. X-rays can induce significant molecular changes in cancer cells.
A Beetz, AP Patel, BL Davidson, C Roller, Cancer Genome Atlas Research Network, D E Hallahan, DA Boothman, DA Reardon, DA Spencer, DE Hallahan, DY Dadey, F Tameire, G Bajocchi, H Hsu, H Li, H Yan, HO McCarthy, JJ Mezhir, K Daino, L N Kaliberova, LM Hendershot, M Gonzalez-Gronow, M Hamdi, M Martin, M Westphal, MA Arap, MJ Gray, N Belousova, N Mittereder, R Datta, R Stupp, R Stupp, RJ Passarella, RR Weichselbaum, S A Kaliberov, S Akli, S Mittal, S Parisi, S Takahashi, SA Kaliberov, SC Noureddini, SL Eck, SS Talibi, T Ichikawa, TA Ajith, TC He, Ulasov IV, V Kapoor, VN Krasnykh, WL Blalock, WW Zhang, X Xing, Y Touchefeu, Y Zhang, YL Tsai   +54 more
core   +2 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Oncolytic herpes simplex virus and immunotherapy [PDF]

BMC Immunology, 2018
Oncolytic viruses have been proposed to be employed as a potential treatment of cancer. Well targeted, they will serve the purpose of cracking tumor cells without causing damage to normal cells. In this category of oncolytic viral drugs human pathogens herpes simplex virus (HSV) is especially suitable for the cause. Although most viral infection causes
Wenqing Ma, Hongbin He, Hongmei Wang
openaire   +3 more sources

Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer

Molecular Therapy: Oncology
Lung cancer’s intractability is enhanced by its frequent resistance to (chemo)therapy and often high relapse rates that make it the leading cause of cancer death worldwide.
Giti Esmail Nia, Elahe Nikpayam, Molood Farrokhi, Azam Bolhassani, Ralph Meuwissen   +4 more
doaj   +1 more source

Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes

Communications Biology, 2022
A secondary (but not primary) dose of the oncolytic virus, VSV, is captured by monocytes and promotes CD8 + T cell recruitment, thereby revealing a mechanism underlying the clinical benefit of repeat dosing in oncolytic virus therapy.
Victor Naumenko, Jahanara Rajwani, Madison Turk, Chunfen Zhang, Mandy Tse, Rachelle P. Davis, Daesun Kim, Andrea Rakic, Himika Dastidar, Shinia Van, Laura K. Mah, Esha K. Kaul, Vladimir P. Chekhonin, Douglas J. Mahoney, Craig N. Jenne   +14 more
doaj   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Macrophage Extracellular Traps in Immunity and Cancer

Advanced Science, EarlyView.
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li, Eugenie Nepovimova, Adam Grundel, Lukas Peter, Qinghua Wu, Kamil Kuca   +5 more
wiley   +1 more source

Giving Oncolytic Vaccinia Virus More BiTE [PDF]

Molecular Therapy, 2014
Two of the most exciting new areas of cancer therapy are the use of oncolytic viruses and immune-stimulating monoclonal antibodies. Each approach has shown great promise in animal models and some successes in early clinical trials, but there remain significant barriers to highly effective therapy.
Albelda, Steven M, Thorne, Steve H
openaire   +2 more sources